Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 2,500,000 shares of Knight Therapeutics stock in a transaction dated Friday, March 21st. The shares were sold at an average price of C$6.30, for a total transaction of C$15,750,000.00.
Sime Armoyan also recently made the following trade(s):
- On Wednesday, March 19th, Sime Armoyan sold 550,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.20, for a total transaction of C$3,410,000.00.
- On Monday, March 17th, Sime Armoyan sold 92,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.15, for a total value of C$567,030.00.
- On Thursday, March 13th, Sime Armoyan sold 1,100 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.10, for a total value of C$6,710.00.
- On Tuesday, March 4th, Sime Armoyan bought 17,600 shares of Knight Therapeutics stock. The stock was purchased at an average price of C$5.48 per share, with a total value of C$96,488.48.
Knight Therapeutics Stock Performance
Shares of GUD stock opened at C$5.97 on Tuesday. The firm has a market cap of C$603.87 million, a price-to-earnings ratio of -19.93, a PEG ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics Inc. has a 52-week low of C$5.09 and a 52-week high of C$6.45. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. The company's 50 day moving average is C$5.69 and its 200 day moving average is C$5.58.
Wall Street Analysts Forecast Growth
Separately, Research Capitl upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th.
Check Out Our Latest Stock Report on Knight Therapeutics
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
